Nivolumab in Combination With Talazoparib in Melanoma and Mutations in BRCA or BRCA-ness Genes
Status:
Recruiting
Trial end date:
2024-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate how effective the study drugs, nivolumab (also known
as Opdivo®) and talazoparib (also known as Talzenna®) are when given as a combination
treatment for unresectable or metastatic melanoma. The study team wants to know the
effectiveness of these drugs together in treating cancer than if each study drug was given by
itself.